Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation

Haematologica

Volumn 99, Issue 2, 2014, Pages 346-352

  Uhlin, Michael ^a,b   Wikell, Helena ^a,b   Sundin, Mikael ^a,b   Blennow, Ola ^a,b   Maeurer, Markus ^a,b   Ringden, Olle ^a,b   Winiarski, Jacek ^a,b   Ljungman, Per ^b   Remberger, Mats ^a,b   Mattsson, Jonas ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOSPORIN; METHOTREXATE; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STROMA CELL; POLYMERASE CHAIN REACTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROPHYLAXIS; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK FACTOR; SEROLOGY; SPLENECTOMY; SURVIVAL RATE;

ALLOGRAFTS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84896691028     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.087338     Document Type: Article

References (30)

1. Baade PD, Youlden DR, Chambers SK. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust. 2011;194(2):73-7.
2. Ellison LF, Bryant H, Lockwood G, Shack L. Conditional survival analyses across cancer sites. Statistics Canada, Catalogue no 82*003-XPE, Health Reports. 2011;22(2):1-5.
3. Moller MB, Pedersen NT, Christensen BE. Conditional survival of patients with diffuse large B-cell lymphoma. Cancer. 2006;106 (10):2165-70.
4. Netherlands Cancer Registry. www.cijfersoverkanker.nl [Internet].
5. Fritz, A, Percy, C, Jack, A. International Classification of Diseases for Oncology, 3rd edition. Geneva: World Health Organization; 2000.
6. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphoma. Cancer Treat Rep. 1997;61: 1023-7.
7. The Council of the Federation of Medical Scientific Societies, The Netherlands. The code of conduct for medical research [Internet]. http://www.federa.org/codesconduct
8. Swerdlow, SH, Campo, E, Harris, NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, editor. Lyon: 2008.
9. Ederer, F, Heise, H. Instructions to IBM650 Programmers in Processing Survival Computations. Bethesda MD: National Cancer Institute; 1959.
10. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer. 1996;78(9):2004-10.
11. Houterman S, Janssen-Heijnen ML, van de Poll-Franse LV, Brenner H, Coebergh JW. Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis. Ann Oncol. 2006;17(4):709-12.
12. Brenner H, Rachet B. Hybrid analysis for upto-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer. 2004;40(16):2494-501.
13. Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006;164(7):689-96.
14. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M, ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi50-4.
15. Dreyling M. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v181-3.
16. Zucca E, Dreyling M. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v175-6.
17. Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1994;86(19):1450-7.
18. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22(10):1864-71.
19. Oerlemans S, Mols F, Issa D, Pruijt J, Peters W, Lybeert M, et al. A high level of fatigue among long-term survivors of non-Hodgkin's lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands. 2013;98(3):479-86.
20. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004;104(5):1258-65.
21. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, Houterman S, Verheij KD, Coebergh JW. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol. 2005;129(5): 597-606.
22. van de Schans SA, Janssen-Heijnen ML, Nijziel MR, Steyerberg EW, van Spronsen DJ. Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting. Haematologica. 2010;95(9):1503-9.
23. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(19):3159-65.
24. Quaglia A, Capocaccia R, Micheli A, Carrani E, Vercelli M. A wide difference in cancer survival between middle aged and elderly patients in Europe. Int J Cancer. 2007; 120(10):2196-201.
25. van de Schans SA, Wymenga AN, van Spronsen DJ, Schouten HC, Coebergh JW, Janssen-Heijnen ML. Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol. 2012;23(5):1280-6.
26. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer. 2005;41(7):1051-7.
27. van Spronsen DJ, Janssen-Heijnen ML, Breed WP, Coebergh JW. Prevalence of comorbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol. 1999;78(7):315-9.
28. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-42.
29. Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, et al. A systematic review and metaanalysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol. 2010;49(1):3-12.
30. Adamson P, Bray F, Costantini AS, Tao MH, Weiderpass E, Roman E. Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer. 2007; 43(2):391-401.